New Alzheimer's drug candidate takes first step in human safety trial
NCT ID NCT07660341
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single intravenous dose of an experimental drug called CGB3002 in healthy adults aged 18 to 55. The main goal is to see if the drug is safe and how the body processes it. This is a first step toward possibly developing a treatment for Alzheimer's disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CGB3002
What this could lead to
If safe, this could open the door to testing CGB3002 as a potential treatment for Alzheimer's disease.
What could go wrong
This is a very early, small study in healthy people, not those with Alzheimer's. It only checks safety and how the drug moves through the body, not whether it works against the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••